Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGP 555 in Healthy Young Volunteers
NCT02534480Phase 1Completed
- Sponsor
- NeuroGenetic Pharmaceuticals
- Start
- Mar 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NGP 555 in Alzheimer's disease (AD) (5 arms), sponsored by NeuroGenetic Pharmaceuticals. Primary endpoint: Number of subjects with adverse events. Started Mar 2015; status: completed.
02
Drugs
NGP 555
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02534480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534480.